Quetiapine for the Management of Tardive Dyskinesia in Schizoaffective Disorder Comorbid With Diabetes Mellitus and Chronic Kidney Disease

Gowda, Shayanth Manche; Madhupreetha, S.; Kumar, Vijay

doi:10.4088/pcc.20l02618

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CYP3A4 enzymes are located in the liver, small and large intestines, testicles or ovaries, duodenum, pancreas, kidneys, spleen, and lymph nodes [ 46 ]. The heart and the kidneys are the main known sites of major QP side effects [ 47 , 48 , 49 ]. As represented in Figure 9 , there was a significant increase in the QP in the rat brain and spleen after IV QP-NPs over the IV or oral QP solutions.…”

Section: Resultsmentioning

confidence: 99%

Quetiapine Albumin Nanoparticles as an Efficacious Platform for Brain Deposition and Potentially Improved Antipsychotic Activity

et al. 2023

View full text Add to dashboard Cite

Quetiapine (QP) is a second-generation short-acting antipsychotic drug extensively metabolized in the liver, producing pharmacologically inactive metabolites and leading to diminished bioavailability. Therefore, this study aimed to develop an intravenous QP albumin nanoparticles (NPs) system for improving QP antipsychotic activity and brain targeting. QP-loaded albumin NPs were prepared by the desolvation method. The fabricated NPs were characterized in terms of particle size, zeta potential, entrapment efficiency (EE%), and in vitro drug release. In vivo pharmacokinetics and biodistribution in rats were studied. In addition, the antipsychotic activity of the optimized platform was also investigated. Human serum albumin (HSA) concentration, pH, and stirring time were modulated to optimize QP albumin NPs with a particle size of 103.54 ± 2.36 nm and a QP EE% of 96.32 ± 3.98%. In addition, the intravenous administration of QP albumin NPs facilitated QP brain targeting with a 4.9-fold increase in targeting efficiency compared to the oral QP solution. The QP albumin NPs improved the QP antipsychotic activity, indicated by suppressing rats’ hypermobility and reducing the QP’s extrapyramidal side effects. The obtained results proposed that intravenous QP- NPs could improve QP brain targeting and its antipsychotic efficiency.

show abstract

Section: Resultsmentioning

confidence: 99%

Quetiapine Albumin Nanoparticles as an Efficacious Platform for Brain Deposition and Potentially Improved Antipsychotic Activity

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Multiple case reports have previously described successfully using quetiapine in the treatment of CTD and tardive dystonia, however, none of these discuss a case with the breadth of tardive syndromes we discuss here 13–21 . A single‐blind randomised trial involved 45 patients, which compared quetiapine and haloperidol for treating CTD showed favourable results for quetiapine 22 .…”

Section: Discussionmentioning

confidence: 99%

Heterogeneous tardive syndromes are still treatable with quetiapine

Curran,

Mellor,

Howarth

2023

Prog Neurol Psychiatry

View full text Add to dashboard Cite

This article presents a case of classical tardive dyskinesia, apparent since at least 1997 when tetrabenazine and clonazepam were prescribed to the patient in addition to risperidone. However, the patient's mental health had been well controlled until sudden cessation of risperidone and the subsequent development of severe classical tardive dyskinesia, tardive dystonia and tardive tics. The authors describe the proposed pathophysiology of tardive dyskinesia, the impure nature of tardive syndromes, the underdiagnosis of tardive tics but eventual successful treatment with quetiapine.

show abstract

Diazepam/risperidone

2022

Reactions Weekly

View full text Add to dashboard Cite

Quetiapine for the Management of Tardive Dyskinesia in Schizoaffective Disorder Comorbid With Diabetes Mellitus and Chronic Kidney Disease

Cited by 3 publications

References 0 publications

Quetiapine Albumin Nanoparticles as an Efficacious Platform for Brain Deposition and Potentially Improved Antipsychotic Activity

Quetiapine Albumin Nanoparticles as an Efficacious Platform for Brain Deposition and Potentially Improved Antipsychotic Activity

Heterogeneous tardive syndromes are still treatable with quetiapine

Diazepam/risperidone

Contact Info

Product

Resources

About